0.40Open0.40Pre Close0 Volume48 Open Interest7.50Strike Price0.00Turnover74.91%IV11.36%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.3300Delta0.2208Gamma20.03Leverage Ratio-0.0106Theta-0.0021Rho-6.61Eff Leverage0.0079Vega
Delcath Systems Stock Discussion
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
Delcath Systems Receives Permanent J-Code For HEPZATO
Delcath Systems Launches Commercial Treatment Utilizing HEPZATO KIT For Treatment Of Metastatic Uveal Melanoma
No comment yet